TruScreen Group Limited (TRU.NZ)
TruScreen Group Limited operates in the Medical - Devices industry of the Healthcare sector, headquartered in Auckland, AU, NZ. The stock last traded at $0.01, up 0.00% on the session, giving a market capitalisation of $10.6M. Its beta of -0.06 implies it has historically moved less than the broad market.
TruScreen Group Limited, alongside its subsidiaries, focuses on the development, manufacturing, and global distribution of advanced systems for cancer detection. Their commercial reach extends across various international territories, including Mexico, China, Russia, Vietnam, Zimbabwe, countries within Eastern Europe, the Middle East/North Africa region, and beyond. A flagship product is the TruScreen cervical cancer screening system, a specialized medical device engineered to provide real-time identification of precancerous and cancerous tissue present on the cervix. Established in 2013, the company, with its primary base of operations in Auckland, New Zealand, officially changed its name from TruScreen Limited to Truscreen Group Limited in August 2020.